Geneos Wealth Management Inc. Purchases 287 Shares of Becton, Dickinson and Company (NYSE:BDX)

Geneos Wealth Management Inc. raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,547 shares of the medical instruments supplier’s stock after purchasing an additional 287 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Becton, Dickinson and Company were worth $630,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BDX. Ridgewood Investments LLC increased its stake in Becton, Dickinson and Company by 1.5% in the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock valued at $731,000 after acquiring an additional 43 shares during the last quarter. Key Client Fiduciary Advisors LLC increased its position in shares of Becton, Dickinson and Company by 2.6% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after purchasing an additional 43 shares during the last quarter. CWM LLC raised its holdings in shares of Becton, Dickinson and Company by 0.7% during the 4th quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock valued at $1,537,000 after buying an additional 46 shares in the last quarter. S.A. Mason LLC lifted its position in Becton, Dickinson and Company by 3.5% in the 4th quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock worth $346,000 after buying an additional 48 shares during the last quarter. Finally, Edge Capital Group LLC boosted its stake in Becton, Dickinson and Company by 3.1% in the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock worth $384,000 after buying an additional 48 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In other news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the sale, the executive vice president now owns 11,308 shares in the company, valued at $2,676,942.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The disclosure for this sale can be found here. Insiders sold a total of 8,615 shares of company stock valued at $2,033,381 over the last three months. Corporate insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BDX. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 27th. Barclays raised their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. Evercore ISI reduced their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, Citigroup decreased their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $280.14.

Becton, Dickinson and Company Trading Up 0.5 %

BDX traded up $1.07 during midday trading on Thursday, reaching $224.94. 1,637,847 shares of the company’s stock traded hands, compared to its average volume of 1,433,974. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $287.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The firm has a fifty day moving average of $233.34 and a two-hundred day moving average of $237.11. The stock has a market capitalization of $65.01 billion, a price-to-earnings ratio of 49.31, a P/E/G ratio of 1.97 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the previous year, the firm earned $2.86 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. On average, equities analysts anticipate that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.69%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.